Clinical Study Results
How many participants had adverse reactions?
There were 13.8% of participants who had adverse reactions during the 3 year
study period. This was 61 out of 443 participants.
• 18.1% of participants who took dapagliflozin, saxagliptin, and metformin had
adverse reactions during the study. This was 41 out of 227 participants.
• 9.3% of participants who took glimepiride and metformin had adverse
reactions during the study. This was 20 out of 216 participants.
There were 1.3% of participants who stopped taking dapagliflozin and saxagliptin
because of adverse reactions they had during the 3 year study period. This was 3
out of 227 participants.
None of the participants stopped taking glimepiride because of adverse reactions
they had during the study.
What adverse reactions did the participants have?
The most common adverse reaction was a urinary tract infection.
The table below shows the most common adverse reactions that happened in 3
or more participants in each treatment group during the 3 year study period. There
were other adverse reactions, but these happened in fewer participants.
Most common adverse reactions during the study
Dapagliflozin, saxagliptin,
Adverse reaction Glimepiride and metformin
and metformin
(out of 216 participants)
(out of 227 participants)
Urinary tract infection 4.8% (11) 2.8% (6)
Weight loss 1.8% (4) 0.0% (0)
Fungal genital infection 1.3% (3) 0.0% (0)
10